Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

The Signaling Pathways Enriched in High-Risk AML Patients Revealed By the Integrative miRNA-mRNA Analysis - Pilot Study

Magdalena Czemerska, Damian Mikulski, Aneta Wisnik, Dariusz Jarych, Izabela Zawlik, Piotr Strzalka, Kinga Krawiec, Wojciech Fendler, Agnieszka Pluta, Agnieszka Wierzbowska

Blood (2023) 142 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2023-174968

Published: 2023

Journal Articles

Evaluation of Neddylation and Apoptosis-Related Gene Expression in Patients with Acute Myeloid Leukemia

Kinga Krawiec, Piotr Strzalka, Dariusz Jarych, Aneta Wiśnik, Michał Soin, Magdalena Góralska, Damian Mikulski, Magdalena Czemerska, Izabela Zawlik, Agnieszka Wierzbowska, Agnieszka Pluta

Blood (2023) 142 (Supplement 1): 5990.

https://doi.org/10.1182/blood-2023-181739

Published: 2023

Journal Articles

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

Blood (2023) 142 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2023-189713

Published: 2023

Journal Articles

Assessment of SIRT1-SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia

Piotr Strzalka, Kinga Krawiec, Dariusz Jarych, Aneta Wiśnik, Michał Soin, Magdalena Góralska, Damian Mikulski, Magdalena Czemerska, Izabela Zawlik, Agnieszka Pluta, Agnieszka Wierzbowska

Blood (2023) 142 (Supplement 1): 6048.

https://doi.org/10.1182/blood-2023-187756

Published: 2023

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Kamil Brzozowski, Magdalena Czemerska, Marta Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan M. Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2023) 142 (Supplement 1): 5914.

https://doi.org/10.1182/blood-2023-181633

Published: 2023

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 11836–11837.

https://doi.org/10.1182/blood-2022-170126

Published: 2022

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Marta Anna Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2022) 140 (Supplement 1): 6165–6166.

https://doi.org/10.1182/blood-2022-163109

Published: 2022

Journal Articles

The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients

Magdalena Czemerska, Aneta Wisnik, Dariusz Jarych, Izabela Zawlik, Piotr Strzałka, Kinga Krawiec, Barbara Cebula-Obrzut, Agata Majchrzak, Kamil Brzozowski, Marcin Kozlowski, Agnieszka Pluta, Agnieszka Wierzbowska

Blood (2022) 140 (Supplement 1): 6252–6253.

https://doi.org/10.1182/blood-2022-156736

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 3206–3207.

https://doi.org/10.1182/blood-2022-166227

Published: 2022

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement — Case Control Study of the Polish Adult Leukemia Group (PALG)

Elżbieta Patkowska, Andrzej Szczepaniak, Marta Baranska, Maciej Kazmierczak, Monika Paluszewska, Wieslaw Jedrzejczak, Renata Guzicka Kazmierczak, Wanda Knopinska Posluszny, Olga Grzybowska-Izydorczyk, Agnieszka Pluta, Jaroslaw Piszcz, Izabela Deren-Wagemann, Ewa Lech Maranda, Krzysztof Warzocha, Joanna Gora Tybor

Blood (2017) 130 (Supplement 1): 1311.

https://doi.org/10.1182/blood.V130.Suppl_1.1311.1311

Published: 2017

Journal Articles

Slower Engraftment in Patients with High Expression of miRNA-15a, miRNA-16, miRNA-126, miRNA-146a, miRNA-223 Prior to Autologous Stem Cell Transplantation and at Early Time after Transplantation

Mateusz Nowicki, MSc, Janusz Szemraj, Prof., Agnieszka Wierzbowska, MD Prof., Małgorzata Misiewicz, PhD, Roman Małachowski, MSc, Agnieszka Pluta, MD PhD, Olga Grzybowska-Izydorczyk, Tadeusz Robak, MD PhD, Anna Szmigielska-Kaplon, MD PhD

Blood (2016) 128 (22): 5717.

https://doi.org/10.1182/blood.V128.22.5717.5717

Published: 2016

Journal Articles

Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)

Blood (2016) 128 (22): 213.

https://doi.org/10.1182/blood.V128.22.213.213

Published: 2016

Journal Articles

Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial

Agnieszka Wierzbowska, MD PhD, Ewa Wawrzyniak, PhD, Agnieszka Pluta, MD PhD, Tadeusz Robak, MD PhD, Grzegorz J. Mazur, MD PhD, Anna Dmoszynska, MD PhD, Jaroslav Cermak, MD PhD, Albert Oriol, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 1336.

https://doi.org/10.1182/blood.V126.23.1336.1336

Published: 2015

Journal Articles

Cladribine Added to Daunorubicin and Cytarabine Induction Regimen Prolongs Survival of Patients with Complex but Not Monosomal Karyotype Acute Myeloid Leukemia – Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2014) 124 (21): 2347.

https://doi.org/10.1182/blood.V124.21.2347.2347

Published: 2014

NARROW

The Signaling Pathways Enriched in High-Risk AML Patients Revealed By the Integrative miRNA-mRNA Analysis - Pilot Study

Evaluation of Neddylation and Apoptosis-Related Gene Expression in Patients with Acute Myeloid Leukemia

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

Assessment of SIRT1-SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement — Case Control Study of the Polish Adult Leukemia Group (PALG)

Slower Engraftment in Patients with High Expression of miRNA-15a, miRNA-16, miRNA-126, miRNA-146a, miRNA-223 Prior to Autologous Stem Cell Transplantation and at Early Time after Transplantation

Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)

Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial

Cladribine Added to Daunorubicin and Cytarabine Induction Regimen Prolongs Survival of Patients with Complex but Not Monosomal Karyotype Acute Myeloid Leukemia – Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only